News
)
11 November 2022
VIVEbiotech presents its highly flexible and customized approach to lentiviral vector manufacturing at BioProcess International
VIVEbiotech has presented a webinar entitled “Flexible and Customized Approach to Lentiviral Vector Development and Manufacture Through a Well-Established Platform” last Tuesday, November 8.
Read more)
24 October 2022
VIVEbiotech participates in the 4th edition of New Culturers Gunea
VIVEbiotech has participated in the 4th edition of New Culturers Gunea that took place in FabrikaNCE last 19th October: a very interesting event to show...
Read more)
21 October 2022
Gurutz Linazasoro, CEO of VIVEbiotech, participates in a conference organized by AseBio and CIBER
Gurutz Linazasoro, CEO of VIVEbiotech, has participated in the conference called "Terapias avanzadas (TA): de la academia a la industria" organized by AseBio, the Spanish...
Read more)
19 October 2022
VIVEbiotech presents its highly optimized transfection process in a webinar with Polyplus
VIVEbiotech has participated in a webinar entitled “The importance of raw materials to succeed in lentiviral vector manufacturing” together with Polyplus.
Read more)
13 October 2022
VIVEbiotech´s scalable, regulatory compliant and cost-effective platform presentation together with Univercells Technologies
VIVEbiotech has participated in a webinar entitled “How to find success with lentiviral production using fixed bed bioreactor technology?” together with Univercells Technologies.
Read more21 September 2022
VIVEbiotech, one of the three only companies to obtain a PERTE
VIVEbiotech has obtained the PERTE called “Salud de Vanguardia/State-Of-The-Art Health” by the Ministry of Industry of the Spanish Government which is financed with European...
Read more)
21 June 2022
VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck
VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited...
Read more)
4 May 2022
Interview with Natalia Elizalde in The Medicine Maker
The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
Read more)
2 May 2022
Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022
The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List
Read more)
7 April 2022
The Analytical Scientist interviews Rakel Lopez de Maturana
The Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.
Read moreDestacadas
)
28 September 2023
VIVEbiotech: A Lentiviral Vector Specialist Bridging the Gap Between R&D and Commercialisation
)
14 September 2023
The Medicine Maker publishes an opinion article after interviewing Natalia Elizalde
)
24 August 2023
)
14 August 2023
Contribution to an article defining the benefits of lentiviruses in BioPharm International
)
)
11 July 2023
)
)
)
4 June 2023
)